Arjun Agarwal Sells 395 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 395 shares of Oruka Therapeutics stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total transaction of $27,527.55. Following the completion of the sale, the senior vice president owned 16,899 shares in the company, valued at approximately $1,177,691.31. This trade represents a 2.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total transaction of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30.

Oruka Therapeutics Stock Down 1.7%

NASDAQ:ORKA opened at $67.71 on Wednesday. The stock has a market cap of $4.08 billion, a P/E ratio of -34.90 and a beta of -0.26. The firm’s fifty day simple moving average is $64.00 and its 200 day simple moving average is $44.58. Oruka Therapeutics, Inc. has a twelve month low of $10.77 and a twelve month high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, analysts expect that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ORKA. Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, April 30th. Wedbush set a $165.00 target price on shares of Oruka Therapeutics in a report on Monday, April 27th. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright restated a “buy” rating on shares of Oruka Therapeutics in a report on Wednesday, June 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $131.30.

Institutional Trading of Oruka Therapeutics

A number of hedge funds have recently modified their holdings of the business. Legal & General Group Plc purchased a new position in shares of Oruka Therapeutics in the 2nd quarter worth about $28,000. BNP Paribas Financial Markets raised its position in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares during the last quarter. Royal Bank of Canada raised its position in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Oruka Therapeutics in the 4th quarter worth about $37,000. Finally, PNC Financial Services Group Inc. purchased a new position in shares of Oruka Therapeutics in the 3rd quarter worth about $39,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.